KALA vs. SPY
KALA (Kala Pharmaceuticals, Inc.) is a stock, while SPY (State Street SPDR S&P 500 ETF) is S&P 500 fund tracking the S&P 500 Index. Over the past 5 years, KALA returned -81.64%/yr vs 13.05%/yr for SPY. At a 0.24 correlation, their price movements are largely independent.
Performance
KALA vs. SPY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KALA achieves a -88.77% return, which is significantly lower than SPY's 8.15% return.
KALA
- 1D
- -11.86%
- 1M
- 28.40%
- YTD
- -88.77%
- 6M
- -89.05%
- 1Y
- -98.45%
- 3Y*
- -83.81%
- 5Y*
- -81.64%
- 10Y*
- —
SPY
- 1D
- -1.45%
- 1M
- -1.36%
- YTD
- 8.15%
- 6M
- 7.20%
- 1Y
- 23.59%
- 3Y*
- 20.68%
- 5Y*
- 13.05%
- 10Y*
- 15.53%
KALA vs. SPY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
KALA Kala Pharmaceuticals, Inc. | -88.77% | -91.99% | -0.86% | -81.65% | -36.94% | -82.15% | 83.74% | -24.54% | -73.55% | 10.72% |
SPY State Street SPDR S&P 500 ETF | 8.15% | 17.72% | 24.89% | 26.18% | -18.18% | 28.73% | 18.33% | 31.22% | -4.57% | 9.14% |
Correlation
The correlation between KALA and SPY is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jul 20, 2017 | 0.24 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KALA vs. SPY — Risk / Return Rank
KALA
SPY
KALA vs. SPY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kala Pharmaceuticals, Inc. (KALA) and State Street SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KALA | SPY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.49 | ||
| Sortino ratioReturn per unit of downside risk | -4.01 | ||
| Omega ratioGain probability vs. loss probability | 0.80 | 1.34 | -0.54 |
| Calmar ratioReturn relative to maximum drawdown | -0.99 | 2.67 | -3.65 |
| Martin ratioReturn relative to average drawdown | -1.18 | 11.92 | -13.10 |
Loading charts...
Drawdowns
KALA vs. SPY - Drawdown Comparison
The maximum KALA drawdown since its inception was -100.00%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for KALA and SPY.
Loading charts...
Drawdown Indicators
| KALA | SPY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -55.19% | -44.81% |
Max Drawdown (1Y)Largest decline over 1 year | -99.79% | -8.88% | -90.91% |
Max Drawdown (3Y)Largest decline over 3 years | -99.79% | -18.76% | -81.03% |
Max Drawdown (5Y)Largest decline over 5 years | -99.99% | -24.50% | -75.49% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.72% | — |
Current DrawdownCurrent decline from peak | -100.00% | -3.17% | -96.83% |
Average DrawdownAverage peak-to-trough decline | -82.09% | -9.04% | -73.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 83.41% | 1.98% | +81.43% |
Volatility
KALA vs. SPY - Volatility Comparison
Kala Pharmaceuticals, Inc. (KALA) has a higher volatility of 42.18% compared to State Street SPDR S&P 500 ETF (SPY) at 4.87%. This indicates that KALA's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KALA | SPY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 42.18% | 4.87% | +37.31% |
Volatility (6M)Calculated over the trailing 6-month period | 91.71% | 9.85% | +81.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 166.55% | 12.50% | +154.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 165.18% | 17.15% | +148.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 132.77% | 17.95% | +114.82% |
Dividends
KALA vs. SPY - Dividend Comparison
KALA has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.03%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KALA Kala Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SPY State Street SPDR S&P 500 ETF | 1.03% | 1.07% | 1.21% | 1.40% | 1.65% | 1.20% | 1.52% | 1.75% | 2.04% | 1.80% | 2.03% | 2.06% |
Frequently Asked Questions
KALA and SPY have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KALA has higher volatility (42.18%) compared to SPY (4.87%). In terms of maximum drawdown, KALA dropped -100.00% vs SPY's -55.19%.
SPY currently has the higher Sharpe Ratio (1.90 vs -0.59), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KALA and SPY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer